| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 4, June 25（Wed.）
Room P (Maesato East, Foyer, Ocean Wing)
- 4P-PM-12
Exploration of Biomarkers Related to Metabolic Syndrome Induced by Atypical Antipsychotics
(1Grad.Sch.Pharm.Sci,Tohoku·Univ., 2Grad.Sch.Pharm.Sci,Tohoku·Univ./Dept.Pharm.Sci,Tohoku·Univ,Hosp)
oHaozhu Wang1, Masamitsu Makawa2, Nariyasu Mano2
Atypical antipsychotics, commonly used in the treatment of schizophrenia, demonstrate efficacy against negative symptoms and are associated with fewer extrapyramidal side effects. However, these medications are also linked to metabolic syndrome (MetS)-like adverse reactions, including increased appetite, weight gain, and hyperglycemia, posing significant clinical challenges. In our previous study, we observed significant alterations in phosphatidylcholine (PC) and sphingomyelin (SM) levels in an in vitro model of HepG2 metabolic dysfunction induced by olanzapine treatment. In this study, we employed maternal perinatal administration of the methylating agent methylazoxymethanol acetate (MAM) to establish and validate a schizophrenia mouse model. We examined body weight changes and hepatic alterations following chronic olanzapine administration, while quantitatively assessing PC and SM variations using LC-MS/MS. Our findings revealed significantly greater body weight changes in olanzapine-treated mice compared to untreated controls. Lipid extraction using methanol/water/formic acid enabled successful isolation and quantification of PC and SM in tail blood samples from MAM model mice. Results demonstrated significant dynamic changes in PC and SM levels at days 1, 10, 21, and 31 post-administration. These findings suggest that PC and SM may serve as potential lipid biomarkers for olanzapine-induced metabolic abnormalities associated with MetS.